Skip to main content
2023 BMES Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

    Drug Delivery

    (I-336) Enhancing mRNA-Based Therapeutic Delivery with Coacervate-Encapsulating Polymersomes

    Friday, October 13, 2023
    3:30 PM – 4:30 PM PDT
    Location: Exhibit Hall - Row I - Poster # 336
    Introduction:: mRNA-based therapies have gained significant attention in recent years due to their potential to treat a wide range of diseases, including cancers, immune diseases, and neurological disorders. Specifically, the COVID-19 vaccine is an mRNA-based therapy. Compared to traditional genetic modification methods, mRNA therapies offer lower risk of undesired genetic mutations, transient expression, and rapid production. Naked mRNA cannot be delivered effectively to target tissues due to its susceptibility to degradation by enzymes in the bloodstream and its inability to independently cross the cell membrane. However, current non-viral vectors such as liposomes, polymers, and nanoparticles still face limitations in their ability to deliver mRNA including low encapsulation efficiency, potential toxicity, and limited stability. To address these challenges, we investigate the use of droplet microfluidics to synthesize double-emulsion polymersomes that encapsulate an inner aqueous region. These polymersomes can encapsulate and protect mRNA coacervates, which are condensed phases (liquid-liquid phase separation) formed by the aggregation of RNA and a polyanionic molecule. This approach aims to capitalize on coarcervates’ natural affinity for mRNA molecules to provide protection and facilitate endocytosis, thereby enhancing delivery efficacy and overcoming the current limitations of non-viral vectors. Furthermore, the polyanionic compartment is temperature responsive, allowing for controlled release of mRNA from coacervates. Using this technique, we aim to provide an effective and controlled encapsulation method and drug delivery system for mRNA-based therapeutics.

    Materials and Methods:: A capillary-based microfluidic device was assembled by connecting two chromatography tees with a central square capillary to align two enclosed tapered capillaries for the breakup zone. An oil phase containing dissolved polyethylene glycol-b-poly lactic acid (PEG-PLA) was simultaneously injected with inner and outer aqueous streams to form submicron polymersomes. Polymersome characteristics were optimized through controlling the degree of capillary tapers as well as varying stream flowrates. Polymersomes were collected, resuspended, and characterized through dynamic light scattering (DLS) to determine size and polydispersity index. In addition, we optimized the coacervation of green fluorescent protein (GFP)-coding mRNA and polycation spermine within the same inner aqueous stream composition to facilitate coacervate encapsulation within polymersomes. Turbidity studies using UV/Vis spectroscopy were conducted to determine coacervate stability and the optimal ratio of coacervate components.

    Results, Conclusions, and Discussions:: Results and Discussion: Microfluidic synthesis of polymersomes was confirmed via preliminary DLS characterization (Figure 1). The polymersomes were found to have an average size of 306.5 nm +/- 32.6 nm with an average PDI of 0.52 +/- 0.1, which can be further decreased using extrusion. Turbidity studies conducted under the specified inner aqueous stream conditions revealed an optimal concentration of green fluorescent protein-coded mRNA in spermine to ensure desired coacervate size and stability. Given the design of the microfluidic device and the optimized coacervation process, we anticipate the successful encapsulation of mRNA coacervates within polymersomes under optimized inner aqueous conditions. Moreover, the spermine in the coacervates will provide protection to the mRNA, preventing its contact with the oil stream and decreasing mRNA degradation.

    Conclusions: Using a capillary-based droplet microfluidics approach, PEG-PLA polymersomes can be formed with an inner aqueous phase that not only offers protection to the encapsulated cargo from harsh, degrading solvents, but additionally provides a novel opportunity to encapsulate mRNA/spermine coacervates which could potentially overcome current delivery limitations for mRNA-based therapeutics. Optimization of coacervate formation under inner aqueous conditions provides evidence for future high encapsulation efficiency and protection from mRNA degradation. Further studies need to be conducted to confirm coacervate-loaded polymersome characteristics and measure encapsulation efficiency. Next steps will involve determining encapsulation efficiency by quantifying the unencapsulated mRNA and confirming mRNA release.



    Acknowledgements (Optional): : This work was partially funded through Clemson’s Creative Inquiry Program.

    References (Optional): :